<DOC>
	<DOCNO>NCT00428311</DOCNO>
	<brief_summary>Cardiovascular risk factor cluster hyperandrogenic woman - include present polycystic ovary syndrome - association insulin resistance , obesity , metabolic disorder . The present clinical trial intend compare effect oral contraceptive metformin PCOS patient , focus classic non-classic cardiovascular risk marker index cardiovascular performance , order whether , suspect previous data obtain non-hyperandrogenic woman , oral contraceptive worsen cardiovascular risk profile PCOS woman , favor use metformin latter actually ameliorate risk .</brief_summary>
	<brief_title>Effects Metformin v Oral Contraceptives CV Risk Markers PCOS</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Polycystic Ovary Syndrome</mesh_term>
	<mesh_term>Hyperandrogenism</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Ethinyl Estradiol</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Contraceptives , Oral</mesh_term>
	<mesh_term>Cyproterone</mesh_term>
	<mesh_term>Cyproterone Acetate</mesh_term>
	<mesh_term>Contraceptive Agents</mesh_term>
	<criteria>Women fertile age present PCOS Nonhyperandrogenic woman fertile age ( woman receive intervention serve obtain normative data variable ) Severe disease related condition study Pregnancy Medical surgical treatment PCOS previous 3 month Contraindication use oral contraceptive metformin Inability understand proposal study preclude effective informed consent Minors accompany legal representative</criteria>
	<gender>Female</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>January 2007</verification_date>
	<keyword>Polycystic ovary syndrome</keyword>
	<keyword>Hyperandrogenism</keyword>
	<keyword>Hirsutism</keyword>
	<keyword>Cardiovascular risk</keyword>
	<keyword>Chronic inflammation</keyword>
	<keyword>Metformin</keyword>
	<keyword>Cyproterone acetate</keyword>
	<keyword>Oral contraceptive</keyword>
</DOC>